SCHEDULE 13G: FMR LLC & Abigail Johnson Boost Ultragenyx Stake to 8.3%

FMR LLC and Abigail P. Johnson have disclosed beneficial ownership of 8.3% of Ultragenyx Pharma Inc.'s common stock as of September 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson jointly reported beneficial ownership of 7,964,937.47 shares of Ultragenyx Pharma Inc. common stock.
• This represents 8.3% of the total outstanding common stock of Ultragenyx Pharma Inc.
• FMR LLC holds sole voting power over 7,548,142.00 shares and sole dispositive power over 7,964,937.47 shares.
• Abigail P. Johnson, as a control person of FMR LLC, is deemed to beneficially own the same aggregate amount of shares with sole dispositive power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Ultragenyx Pharma Inc.

Sentiment

Score: 6

Explanation: The filing indicates a significant institutional investment, which is generally positive for investor confidence, but it is a routine ownership disclosure without specific operational or financial news.

Positives

• Increased institutional ownership by a major investment firm like FMR LLC (Fidelity) can signal confidence in Ultragenyx Pharma Inc.'s long-term prospects.
• The filing explicitly states the acquisition is in the ordinary course of business, not for control, which suggests a passive investment intent.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Ultragenyx Pharma Inc.'s future performance or operations, as it is an ownership disclosure.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

The disclosure of a significant stake by a major asset manager like FMR LLC in a biotechnology company such as Ultragenyx Pharma Inc. is a common occurrence in the pharmaceutical and biotech sectors, where institutional investors frequently take positions in companies with promising pipelines or market positions. This indicates continued institutional interest in the sector.

Stakeholder Impact

• Shareholders: Increased institutional ownership may enhance market confidence and liquidity.
• Management: May feel increased scrutiny or validation from a significant institutional investor.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant, passive investment by FMR LLC and Abigail P. Johnson in Ultragenyx Pharma Inc. While increased institutional ownership can be a positive signal of confidence, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a substantial stake, suggesting investors should 'hold' their current positions while awaiting further fundamental news from the company.

Keywords

Ultragenyx Pharma Inc, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals